News

Latest news

16th March 2022

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

22nd February 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

15th February 2022

ニュートンバイオキャピタル、当初出資約束金額5000万ユーロ・目標規模1億5000万ユーロのファンドを新たに設立

15th February 2022

Newton Biocapital launches a new fund with initial capital commitments of EUR 50 million and target size of EUR 150 million.

13th January 2022

Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer

11th January 2022

PRISM、Roche社とGenentech社と共同研究・ライセンス契約を締結

5th October 2021

Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)

29th September 2021

ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris

9
10
11
12
13